Join PER® September 15th for the New York Advanced Practice Collaborative Meeting! Directed toward NP/PAs, this meeting blends presentations on cutting-edge information with panel discussions to enhance learning.

Erica Fischer-Cartlidge Discusses Oral Mucositis Treatment for Patients Taking an mTOR Inhibitor

ERICA FISCHER-CARTLIDGE MSN, CNS, CBCN, AOCNS | April 23, 2015
Erica Fischer-Cartlidge MSN, CNS, CBCN, AOCNS, Clinical Nurse Specialist, Outpatient Breast Medicine Service, Memorial Sloan Kettering Cancer Center, discusses the difference between oral mucositis in patients receiving chemotherapy and patients taking an mTOR inhibitor.

Fischer-Cartlidge says when oral mucositis presents in a patient taking an mTOR inhibitor, it looks and acts differently than oral mucositis in patients receiving chemotherapy.

Fortunately, the oral mucositis in patients taking an mTOR inhibitor responds to steroids better than oral mucositis that presents in patients receiving chemotherapy. The steroid actually healed the oral mucositis instead of just controlling it, Fishcer-Cartlidge says, reducing the need for dose reduction.

<<< View more from the 40th Annual ONS Congress



External Resources

MJH Associates
American Journal of Managed Care
Cure
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
TargetedOnc
OncNurse Resources

Newsroom
Continuing Education
Discussions
Web Exclusives


About Us
Advertise
Advisory Board
Careers
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2018
Intellisphere, LLC. All Rights Reserved.